News | November 17, 2010

Doubling Dose of Clopidogrel Does Not Improve Outcomes Post-PCI

November 17, 2010 - Results from the GRAVITAS Trial found that doubling the maintenance dose of clopidogrel (Plavix) did not reduce the risk of further ischemic events after percutaneous coronary intervention (PCI). The study also reported patients with high residual platelet reactivity demonstrated almost twice the risk of ischemic events compared to patients without high residual platelet reactivity.

Patients were categorized as having high residual platelet reactivity based on the VerifyNow P2Y12 Test. The test is used to measure the antiplatelet effect of medications that reduce platelet reactivity by blocking the platelet P2Y12 receptor.

"The GRAVITAS findings do not support a uniform treatment strategy of high dose clopidogrel in patients with high residual platelet reactivity based upon a single platelet function test after stent implantation,” said Matthew J. Price, M.D., of the Scripps Translational Science Institute and Scripps Clinic in La Jolla, Calif., and principal investigator of the trial. “This is important as currently many physicians utilize a strategy of doubling the dose of clopidogrel the morning after the stent procedure. Alternative therapies or testing a patient multiple times to treat to a specific target of reactivity deserve consideration."

"The GRAVITAS trial provides further evidence of the association between high residual platelet reactivity, sometimes referred to as non-responsiveness, and the occurrence of cardiovascular events,” said Jeffrey R. Dahlen, Ph.D, vice president of clinical and regulatory affairs for Accumetrics “The trial demonstrated a strong trend towards greater risk of ischemic events in non-responders, which is consistent with prior reports. As we further analyze the data, we expect to release additional information that continues to support the value of platelet function testing."

The VerifyNow system is the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents. It is widely used where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events, such as heart attack and stroke. Clopidogrel is an oral antiplatelet agent sold under the brand name Plavix.

The GRAVITAS study is the first multi-center, placebo-controlled study to determine whether high maintenance dose of clopidogrel therapy reduces ischemic events post-PCI based on the VerifyNow test.

For more information: www.accumetrics.com

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme